Received Feb 4, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | UNK | — |
HIV; Received the one vile presentation of Menveo instead of 2 vial; Received the one vile presentation of Menveo instead of 2 vial; This serious case was reported by a nurse via sales rep and described the occurrence of hiv infection in a 2-year-old male patient who received Men ACWY-CRM NVS (Menveo) for prophylaxis. On an unknown date, the patient received the 1st dose of Menveo. On an unknown date, an unknown time after receiving Menveo, the patient experienced hiv infection (Verbatim: HIV) (serious criteria GSK medically significant), inappropriate preparation of medication (Verbatim: Received the one vile presentation of Menveo instead of 2 vial) and inappropriate dose of vaccine administered (Verbatim: Received the one vile presentation of Menveo instead of 2 vial). The outcome of the hiv infection was not resolved and the outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. The reporter considered the hiv infection to be related to Menveo. The company considered the hiv infection to be unrelated to Menveo. Additional Information: GSK Receipt Date: 29-JAN-2026 Reporter stated that patient had HIV and received one vial presentation of Menveo instead of 2 vials. The batch number was not provided and a request for this information has been made.; Sender's Comments: A case of HIV infection, unknown time after receiving 1st dose of Menveo in a 2-year-old male patient. Case lacks further information on medical history, concurrent conditions and laboratory confirmation. Based on the available information, a possible causality that the event(s) was caused by the GSK product cannot be ascertained. Further follow up information has been sought.